Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine Loading Dose PK in NTM Disease
NCT05294146Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofazimine in non-tuberculous mycobacterial disease (NTM), sponsored by Radboud University Medical Center. Primary endpoint: Pharmacokinetic parameters of clofazimine after a loading dose regimen at Day 28. Started Feb 2022; status: completed.
02
Drugs
clofazimine
03
Conditions
non-tuberculous mycobacterial disease (NTM)
Beyond the preview
Go deeper on NCT05294146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294146.